Cancer research and treatment center
Appears in 5 stories · Last updated Oct 26, 2026
Co-led the PROTEUS substudy with principal investigator Mary-Ellen Taplin
Apalutamide taken for six months before and after prostate cancer surgery cut the risk of recurrence or death by 62% compared with surgery alone in a 408-patient substudy of the PROTEUS trial. Johnson & Johnson reported the results on Oct. 24, 2026; they were presented at the ESMO Congress in Madrid and accepted for publication by European Urology.
Updated Oct 26
Home institution of the presenting investigator for DeLLphi-305
Small cell lung cancer that has spread through the chest and beyond has held median survival near a year for decades. A phase 3 trial presented Oct. 24 at the ESMO Congress raised that to 21.1 months, about eight months longer than the comparison arm.
Building its first dedicated inpatient hospital
Dana-Farber Cancer Institute broke ground on Oct. 19 on a 300-bed hospital built solely for cancer patients, the first inpatient facility of its kind in the Boston region. The $1.68 billion Lavine Bekenstein Cancer Hospital, set to open in 2031 on the former Joslin Diabetes Center site, will have 30 intensive care beds and four floors with specialized air protection for patients with weakened immune systems.
Updated Oct 20
As of September 2026: Hosted the study
Pancreatic cancer ignores nearly every approved immunotherapy, and the new KRAS inhibitors shrink tumors only until resistance emerges. A study published online this week in Cell pairs those inhibitors with a designer mimic of the immune signal IL-21 — and in mice, the combination cleared pancreatic tumors and kept them clear for months.
Updated Sep 24
As of September 2026: Led the ImmunoPRISM trial
Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.
Updated Sep 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
